Cite
HARVARD Citation
Ishola, D. et al. (2022). Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial. Lancet infectious diseases. 22 (1), pp. 97-109. [Online].